HCW Biologics Inc
HCWB
查看详细走势图
1.490USD
-0.067-4.30%
收盘 12/24, 13:00（美东）报价延迟15分钟
3.91M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-4.30%
5天
-14.12%
1月
-31.34%
6月
-65.90%
今年开始到现在
-91.65%
1年
-90.64%
查看详细走势图
TradingKey HCW Biologics Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
HCW Biologics Inc当前公司基本面数据相对谨慎，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名199/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价35.00。中期看，股价处于下降通道。近一个月，市场表现非常差，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
HCW Biologics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
35.000
目标均价
+1676.65%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
HCW Biologics Inc亮点
亮点风险
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
业绩增长期
公司处于发展阶段，最新年度总收入2.57M美元
利润高增长
公司净利润处于行业前列，最新年度总收入2.57M美元
估值高估
公司最新PE估值-0.11，处于3年历史高位
机构减仓
最新机构持股36.93K股，环比减少60.26%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值0.00
活跃度增加
近期活跃度增加，过去20天平均换手率0.68
HCW Biologics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
HCW Biologics Inc简介
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
公司代码HCWB
公司HCW Biologics Inc
CEOWong (Hing C)
网址https://hcwbiologics.com/
常见问题
HCW Biologics Inc(HCWB)的当前股价是多少？
HCW Biologics Inc(HCWB)的当前股价是 1.490。
HCW Biologics Inc的股票代码是什么？
HCW Biologics Inc的股票代码是HCWB。
HCW Biologics Inc股票的52周最高点是多少？
HCW Biologics Inc股票的52周最高点是41.200。
HCW Biologics Inc股票的52周最低点是多少？
HCW Biologics Inc股票的52周最低点是1.515。
HCW Biologics Inc的市值是多少？
HCW Biologics Inc的市值是3.91M。
HCW Biologics Inc的净利润是多少？
HCW Biologics Inc的净利润为-30.02M。
现在HCW Biologics Inc(HCWB)的股票是买入、持有还是卖出？
根据分析师评级，HCW Biologics Inc(HCWB)的总体评级为买入，目标价格为35.000。
HCW Biologics Inc(HCWB)股票的每股收益（EPS TTM）是多少
HCW Biologics Inc(HCWB)股票的每股收益（EPS TTM）是-13.960。
相关品种
